Cagrilintide research guide
Lipidated amylin analogue with amylin and calcitonin receptor activity
Cagrilintide identity, receptor studies and human trial evidence, with single-compound research kept separate from cagrilintide–semaglutide combinations.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
Cagrilintide is a lipidated peptide analogue of amylin, also called AM833 or 0833 in research records. Its development involved changes intended to support a longer-acting analogue. Receptor experiments describe activity at amylin and calcitonin receptors. CagriSema denotes a combination involving cagrilintide and semaglutide; it is not another name for cagrilintide alone.
02 · Evidence position
What the literature can support
The evidence includes receptor pharmacology and randomised human studies of specified formulations. Single-compound and combination trials answer different questions. Read the population, comparator, duration and endpoint beside each finding; neither type of trial establishes the identity or performance of a catalogue vial. The records below are selected primary studies, not a claim about the latest development phase.
03 · Study-level map
Evidence and its limits
Which receptor profile was measured?
A 2021 pharmacology study compared AM833 with other calcitonin-family agonists across receptor binding, activation and regulation assays. It characterised AM833 as an agonist at both amylin and calcitonin receptors.
Limit: An assay profile depends on the receptor system and endpoint. It does not make cagrilintide interchangeable with every amylin analogue or verify a supplier sample.
What did the single-compound trial examine?
The 2021 phase 2 trial followed 706 adults with overweight or obesity without diabetes over 26 weeks. Cagrilintide groups had greater mean body-weight reduction than placebo; gastrointestinal events and treatment discontinuations were also assessed.
Limit: The finding belongs to the specified clinical formulation, trial population and analysis. It is not a result for an APS research presentation.
How is the combination evidence different?
The 2025 REDEFINE 1 trial randomised 3,417 adults without diabetes to cagrilintide–semaglutide, either component alone or placebo. The combination produced greater mean body-weight reduction than placebo at 68 weeks, with more gastrointestinal adverse events.
Limit: Combination findings cannot be assigned to cagrilintide alone. Comparator, analysis method and tolerability remain part of the interpretation.
04 · Analytical context
Questions a batch record should answer
- 01Does the material specification identify cagrilintide and its relevant peptide modifications rather than only a broad amylin label?
- 02Is the stated vial amount supported by a quantitative result with its reporting basis, separately from chromatographic purity?
- 03Which sample and lot identifiers connect any supplied report to the material offered, and which requested properties were actually tested?
05 · Boundary conditions
What this record does not establish
- A single-compound listing does not contain semaglutide unless that separate ingredient is explicitly specified.
- The selected clinical studies do not establish equivalence between their formulations and independently supplied laboratory material.
- No matching APS analytical report for the listed Cagrilintide formats was verified for this guide; purity, content and lot traceability must not be inferred from another supplier.
Sources checked
- 1.Development and structure–activity work on cagrilintide
Kruse et al. — Journal of Medicinal Chemistry · 2021 · Primary study
- 2.AM833 pharmacology across calcitonin-family receptor assays
Fletcher et al. — Journal of Pharmacology and Experimental Therapeutics · 2021 · Primary study
- 3.Cagrilintide monotherapy in a 26-week randomised trial
Lau et al. — The Lancet · 2021 · Primary study
- 4.Coadministered cagrilintide and semaglutide: REDEFINE 1
Garvey et al. — New England Journal of Medicine · 2025 · Primary study
- 5.0839 as a preclinical tool for studying amylin analogues
Gabery et al. — Life Sciences · 2025 · Primary study